.jpg)
21 hours ago
3
Article content
- Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds
- 100% diabetic wound closure in ≤ 12 weeks
- Preclinical sustained antibiofilm activity for a minimum of 7 days
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
WINNIPEG, Manitoba, Nov. 04, 2025 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) today announced new clinical and pre-clinical data demonstrating the performance of its FDA-cleared revyve® Antimicrobial Wound Gel and revyve Wound Gel Spray in both diabetic foot ulcer healing and burn wound infection control. The findings were recently presented at two major U.S. medical meetings: Diabetic Foot Conference (DFCon 2025), held October 23-25 in Anaheim, California, and the Southern Region Burn Conference held October 30-November 2 in Charleston, South Carolina.
Article content
Article content
Article content
Article content
Article content
Article content
US FDA 510(k) cleared revyve
Antimicrobial Wound Gel and
revyve Antimicrobial Wound
Gel Spray
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Clinical Data: Outperforming the Standard of Care
Article content
At DFCon 2025, Dr. Raymond Abdo, DPM (St. Louis Foot and Ankle Institute) and Dr. Peter Moyer, DPM (Foot & Ankle Institute of the Carolinas) presented data showing revyve achieved healing outcomes exceeding the current standard of care for diabetic foot ulcers (DFUs):
Article content
- 97% average Percent Area Reduction (PAR) in 4 weeks, compared to the 40 – 50% PAR benchmark¹
- Complete wound closure within 8–12 weeks in all cases across a multi-center series
- Sustained infection control and reduced bacterial bioburden throughout healing
Article content
“The usage of revyve gel has helped my patient proceed with increased healing wounds by keeping bacteria and bioburden at bay for hard to heal ulcerations,” said Dr. Abdo.
Article content
“revyve is a great product for diabetic ulcers. It utilizes advanced skin healing technology to promote faster and more effective wound healing by managing biofilm. revyve has helped manage my diabetic patients with Peripheral Arterial Disease, hemodialysis, and elevated A1c,” said Dr. Moyer.
Article content
Article content
Rapid Antimicrobial Efficacy in Burn Care
Article content
At the 2025 Southern Region Burn Conference, Dr. Mack Drake, DO, FACS (Burn and Reconstructive Centers of America) presented pre-clinical data demonstrated 99.99 – 99.9999% reduction in burn-associated pathogens within 30 minutes of application. Additionally, sustained antibiofilm activity was seen for 7 days.
Article content
“revyve’s ability to achieve up to a six-log reduction in microbial load within minutes, while maintaining antibiofilm protection for at least seven days, represents a significant advancement in burn wound management — reducing the frequency of dressing changes and helping ease the overall burden of care for patients”, said Dr. Drake.
Article content
These meeting results are part of the second pillar of Kane’s three-pillar strategy to significantly impact wound care in the United States:
Article content
- Conduct a U.S.-based case series demonstrating the clinical use of revyve.
- Report data at leading U.S. wound and burn care meetings.
- Rebuild the U.S. distributor and sales agent network.
Article content
“These findings underscore revyve’s ability to improve upon the standard of care in both diabetic foot and burn management,” said Dr. Robert Huizinga, Interim CEO of Kane Biotech. “revyve’s antibiofilm and antimicrobial technology continues to demonstrate its potential to transform wound healing outcomes.”
English (US)